The MarketWatch News Department was not involved in the creation of this content. The JADA(R) System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join ...

Please provide your email address to receive an email when new articles are posted on . Two postpartum hemorrhage-control devices resulted in similar rates of blood loss, transfusion and device ...

The Organon board of directors has approved the deal. The transaction is expected to close in the first quarter of 2026, subject to required regulatory approvals. “I am incredibly proud of the work ...

Organon & Co. OGN announced the completion of the divestiture of its JADA System to Laborie Medical Technologies Corp. The deal is worth up to $465 million, including $440 million paid at closing and ...

The JADA ® System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join Laborie, strengthening the company's commitment to improving maternal health. Joining an ...